May 13th 2022
Ulka Nitin Vaishampayan, MBBS, discusses the design of the phase 3 PROBE trial in advanced renal cell carcinoma.
December 8th 2021
Ulka Nitin Vaishampayan, MBBS, discusses the utility of FGFR inhibitors in metastatic urothelial cancer.
November 23rd 2021
Ulka Nitin Vaishampayan, MBBS, discusses future directions for second-line treatment in urothelial cancer.
November 6th 2020
Ulka N. Vaishampayan, MBBS, FAB, discusses the expanding role of TKI/immunotherapy combinations in metastatic renal cell carcinoma.
September 15th 2020
Ulka N. Vaishampayan, MBBS, FAB, discusses the safety of tivozanib versus sorafenib in advanced renal cell carcinoma.
September 9th 2020
Ulka N. Vaishampayan, MBBS, FAB, discusses the potential of tivozanib in advanced renal cell carcinoma.
September 3rd 2020
Ulka N. Vaishampayan, MBBS, FAB, discusses the need to develop novel therapies for patients with metastatic renal cell carcinoma.
August 27th 2020
Ulka N. Vaishampayan, MBBS, FAB, discusses the benefit of axitinib and pembrolizumab in advanced renal cell carcinoma.